Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | F2 | P00734 | 3/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.60 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.60 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.60 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.59 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22916896 | 0.84 | CA1 (0.68) | CA1CA2CYP2C19F2PRSS1 | |
| SCHEMBL3245644 | 0.84 | CA1 (0.68) | CA1CA2CYP2C19F2PRSS1 | |
| SCHEMBL30147625 | 0.82 | CA1 (0.66) | CA1CA2CYP2C19F2PRSS1 | |
| SCHEMBL35539 | 0.82 | CA1 (0.66) | CA1CA2CYP2C19F2PRSS1 | |
| SCHEMBL2835612 | 0.82 | CA1 (0.71) | CA1CA2CYP2C19F2PRSS1 | |
| SCHEMBL25517678 | 0.82 | CA1 (0.66) | CA1CA2CYP2C19F2PRSS1 | |
| SCHEMBL30901134 | 0.79 | F2 (0.57) | CA1CA2CYP2C19F2PRSS1 | |
| SCHEMBL1436244 | 0.79 | F2 (0.57) | CA1CA2CYP2C19F2PRSS1 | |
| SCHEMBL30702318 | 0.79 | PFKFB3 (0.76) | CA1CA2AKR1C3KDM4ETSHR | |
| SCHEMBL30702319 | 0.79 | PFKFB3 (0.76) | CA1CA2AKR1C3KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | CA1 4868/4885CA2 4884/4885CYP2C19 958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.